En DE FR ES PL
Omacor - instructions for use, analogs, reviews and release forms (capsules or tablets 1000 mg) of the drug for the treatment of hypertriglyceridemia and lack of omega-3, prevention of myocardial infarction in adults, children and pregnancy. Composition

Omacor - instructions for use, analogs, reviews and release forms (capsules or tablets 1000 mg) of the drug for the treatment of hypertriglyceridemia and lack of omega-3, prevention of myocardial infarction in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Omakor. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Omakor in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Omakor in the presence of existing structural analogs. Use to treat hypertriglyceridemia and lack of omega 3,prevention of myocardial infarction in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

 

Omakor - polyunsaturated essential fatty acids of the omega-3-eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) class are referred to as essential fatty acids (NEFIC).

 

Omacor reduces the triglycerides content as a result of decreasing VLCL concentration, in addition, it actively affects hemostasis, reducing the synthesis of thromboxane A2 and slightly increasing the clotting time.

 

Delays the synthesis of triglycerides in the liver (by inhibiting the esterification of EPA and DHA).

 

A decrease in the level of triglycerides is facilitated by an increase in peroxisomes of beta-oxidation of fatty acids (a decrease in the amount of free fatty acids available for the synthesis of triglycerides).

 

The increase in the concentration of high-density lipoproteins (HDL) is minimal and significantly lower than after taking the fibrates.

 

Clinical results of Omakor drug studies at a dose of 1 g per day for 3.5 years showed a significant reduction in the combined indicator, including total mortality from all causes,as well as non-fatal myocardial infarction and stroke.

 

Composition

 

Omega-3-polyunsaturated fatty acids ethyl esters + auxiliary substances.

 

Pharmacokinetics

 

During and after absorption of omega-3 fatty acids there are 3 main ways of their metabolism:

  • fatty acids are first delivered to the liver, where they are included in the composition of various categories of lipoproteins and are sent to peripheral lipid stocks;
  • phospholipids of cell membranes are replaced by phospholipids of lipoproteins, after which fatty acids can act as precursors of various eicosanoids;
  • most fatty acids are oxidized to provide energy needs.

 

The concentration of fatty acids of the omega-3-EPA and DHA class in blood plasma phospholipids corresponds to the concentration of these fatty acids included in the composition of cell membranes.

 

Indications

 

Hypertriglyceridemia:

  • endogenous hypertriglyceridemia of type 4 according to Fredrickson classification (in monotherapy) as an adjunct to the hypolipidemic diet with its insufficient efficiency;
  • endogenous hypertriglyceridemia 2b or 3 of the Fredrickson classification (in combination with lipid-lowering agents - HMG-CoA inhibitors of reductase (statins)).

 

Secondary prevention of myocardial infarction (as part of combination therapy): in combination with HMG-CoA inhibitors of reductase (statins), antiplatelet agents, beta-adrenoblockers, ACE inhibitors.

 

Forms of release

 

Capsules 1000 mg in a package of 28 or 100 pieces (sometimes mistakenly called pills).

 

Instructions for use and reception scheme

 

The drug is taken orally while eating.

 

In hypertriglyceridemia, the initial dose of Omacor is 2 capsules per day. In the absence of a therapeutic effect, an increase in the dose to a maximum daily dose of 4 capsules is possible. Duration of treatment and repeated courses are established on the recommendation of a doctor.

 

For secondary prevention of myocardial infarction, it is recommended to take 1 capsule per day. Duration of treatment and repeated courses are established on the recommendation of a doctor.

 

Side effect

  • hypersensitivity reactions;
  • hyperglycemia;
  • dizziness;
  • dysgeusia (perversion of taste);
  • headache;
  • marked decrease in blood pressure;
  • dryness of the nasal mucosa;
  • dyspepsia;
  • nausea;
  • abdominal pain;
  • gastrointestinal disorders (gastroesophageal reflux disease, eructation, vomiting,constipation);
  • bleeding from the lower gastrointestinal tract;
  • itching;
  • rash;
  • hives;
  • increase in white blood cell count;
  • hemorrhagic diathesis;
  • with prolonged use of the drug Omakor in large doses (4 grams per day), a belching with a smell or taste of fish is possible.

 

Contraindications

  • exogenous hypertriglyceridemia (hyperchylomicronemia) (type 1 according to Fredrickson classification);
  • pregnancy;
  • lactation period (breastfeeding);
  • age under 18 years (effectiveness and safety not established);
  • hypersensitivity to the active substance, excipients, and also to soy.

 

Application in pregnancy and lactation

 

There are no clinical data on the use of the drug during pregnancy.

 

Prescribe Omakor during pregnancy should be done with caution, only after a thorough assessment of the risk-benefit relationship, when the benefit to the mother exceeds the potential risk to the fetus.

 

The use of Omacor is contraindicated during lactation. If Omacor is needed during lactation, breastfeeding should be discarded.

 

Use in children

 

Contraindicated in children and adolescents under the age of 18 years (efficacy and safety not established).

 

special instructions

 

Due to a moderate increase in bleeding time (when taking a high dose of 4 capsules), patients who have abnormalities from the blood coagulation system, as well as those who receive anticoagulant therapy or drugs that affect the hemostatic system (acetylsalicylic acid as antiplatelet agent, nonsteroidal anti-inflammatory drugs (NSAIDs)), and if necessary - appropriate correction of the dose of anticoagulant or agents affecting the hemostasis system.

 

In patients with impaired liver function (especially when taking a high dose - 4 capsules), regular monitoring of liver function (ACT and ALT) is necessary.

 

The use of Omacor together with Warfarin does not lead to any hemorrhagic complications. However, with combined use of Omacor and warfarin or discontinuation of treatment with Omacor, monitoring of prothrombin time or MHO (international normalized ratio) is necessary.

 

Impact on the ability to drive vehicles and manage mechanisms

 

Studies on the effect of Omakor on the ability to drive vehicles and engage in other potentially hazardous activities,requiring increased concentration of attention and speed of psychomotor reactions, was not conducted.

 

During the period of Omakor drug treatment, care must be taken when driving vehicles and engaging in potentially dangerous activities that require a high concentration of attention and speed of psychomotor reactions.

 

Drug Interactions

 

With the simultaneous use of Omacor with oral anticoagulants and other drugs that affect the hemostatic system, the risk of increasing bleeding time increases.

 

There are no data on simultaneous use with fibrates in the treatment of hypertriglyceridemia.

 

Omacor analogues

 

Omakor does not have structural analogs for the active substance. The drug is unique in the composition of the active substances.

 

Analogues on the pharmacological group (lipid-lowering drugs):

  • Alisat is super;
  • Allie;
  • Allikor;
  • Allylchep;
  • Alliter;
  • Alpha lipoic acid;
  • Ateroclephitis;
  • Vitanorm;
  • Vitrum Omega 3;
  • Kwai;
  • Clam;
  • Xenalten;
  • Xenical;
  • Courdlepid;
  • Lacrinate;
  • Kelp;
  • Lysivitis C;
  • Lipoic acid;
  • Liptiokson;
  • Listat;
  • Octolipen;
  • Optinat;
  • Orlimax;
  • Orlistat;
  • Orsotene;
  • Orsoten Slim;
  • Polisponin;
  • Pollinate;
  • Splatinate;
  • Thiocacid 600;
  • Thiolipone;
  • Tribestan;
  • Tritinate;
  • Tyqveol;
  • Urso 100;
  • Ursodeoxycholic acid;
  • Phytotransit;
  • Ezetrol;
  • Eikonol;
  • Eifitol;
  • Exxhol;
  • Espa Lipon.

Similar medicines:

Other medicines:

Reviews (3):
Visitors
miha-chel1
What is treated for obesity of the liver and remove stones from the gallbladder?
Administrators
admin
miha-chel1Gall stones from the gall bladder are reliably removed only by surgery or by punctures, because any choleretic preparations can lead to incomplete exit of stones and clogging of the bile duct, which eventually leads to complication and emergency surgery. Sometimes in the literature there is an indication of the possibility of dissolution with the help of preparations of ursodeoxycholic and chenodeoxycholic acid,but I have no reliable confirmation or positive experience of use. Omakor here you just do not helper.

With fatty liver dystrophy, the use of essential phospholipids (Essentiale, Essencycaps, etc.) or drugs based on ursodeoxycholic acid (Ursosan and others) is shown. True, if there are stones in the gallbladder and other concomitant pathologies before starting the reception, consultation of the therapist or gastroenterologist is necessary.
Visitors
Nat
Hello. I drank the drug for one month. Feeled bitterness in the mouth, decreased appetite and stopped taking. The cardiologist prescribed this medication for complaints about itching and tingling all over the body in the winter and autumn period, an increased pulse even in a state of rest and extrasystole. To drink it was said during the 3 winter months together with the magnetite. Despite the reduction of itching, I had to stop taking omakor.

Rules for publishing reviews and visitor questions